<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02220634</url>
  </required_header>
  <id_info>
    <org_study_id>HS-2820</org_study_id>
    <nct_id>NCT02220634</nct_id>
  </id_info>
  <brief_title>Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension</brief_title>
  <acronym>RHINO</acronym>
  <official_title>Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if Regadenoson may offer improved ease of use, single&#xD;
      dose administration, and better tolerance for testing for pulmonary hypertension than iNO.&#xD;
      You will be screened to make sure Regadenoson is safe for you with a clinical evaluation,&#xD;
      blood tests, and an ECG.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary hypertension (PH) is an increase of blood pressure in the pulmonary vascular system&#xD;
      that could cause shortness of breath, dizziness, leg swelling and heart failure. .&#xD;
&#xD;
      The diagnosis of PH requires confirmation of elevated pulmonary pressures.. Right heart&#xD;
      catheterization (RHC) is a procedure to determine the diagnosis of PH. .&#xD;
&#xD;
      This research study is looking at the effect of intravenous infusion of the medication&#xD;
      Regadenoson on pulmonary vasodilator response compared to the inhaled nitric oxide (iNO)&#xD;
      response. iNO is the current standard of care practice.&#xD;
&#xD;
      The purpose of this study is to see if Regadenoson may offer improved ease of use, single&#xD;
      dose administration, and better tolerance for testing for pulmonary hypertension than iNO.&#xD;
      You will be screened to make sure Regadenoson is safe for you with a clinical evaluation,&#xD;
      blood tests, and an ECG.&#xD;
&#xD;
      You will be asked to sign this informed consent form. Then, you will undergo right heart&#xD;
      catheterization as part of your clinical care. Those who are positive for pulmonary&#xD;
      hypertension will then undergo Regadenoson infusion and a inhaled iNO. Prior to the infusion,&#xD;
      subjects will be asked if they have had in the last 12 hours any caffeine-containing foods or&#xD;
      beverages, caffeine-containing medications such as theophylline 12 hours prior. Vital sign&#xD;
      measurements will be taken to measure your heart. For those subjects that have low heart&#xD;
      volume they will be given 500 cc of normal saline in their IV. Vital sign measurements will&#xD;
      be taken again to make sure your heart volume is in the normal range. The doctor will&#xD;
      administer Regadenoson 0.4 mg intravenously and this will cause your heart rate to increase.&#xD;
      The doctor will be taking heart measurements 90 seconds, 5 minutes, 10 minutes, and 20&#xD;
      minutes after administration. Approximately 30 minutes after the Regadenoson has been&#xD;
      administered you will be given iNO by facemask for 5 minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left National Jewish Health&#xD;
  </why_stopped>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">May 25, 2017</completion_date>
  <primary_completion_date type="Actual">May 25, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of people</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Regadenoson</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of the A2A agonist regadenoson has a preferential vasodilator effect on pulmonary vasculature that is comparable to iNO, the current gold standard for pulmonary vasoreactivity studies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson</intervention_name>
    <description>Injection for intravenous administration</description>
    <arm_group_label>Regadenoson</arm_group_label>
    <other_name>Lexiscan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-75 years old&#xD;
&#xD;
          2. Diagnosis of RHC-proven PH&#xD;
&#xD;
               -  Mean pulmonary artery pressure (mPAP) &gt; 25 mmHg&#xD;
&#xD;
               -  Pulmonary vascular resistance (PVR) &gt; 3 woods units&#xD;
&#xD;
               -  Pulmonary capillary wedge pressure (PCWP) &lt; 15 mmHg).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Second- or third-degree AV block or sinus node dysfunction&#xD;
&#xD;
          2. Known hypersensitivity to adenosine or regadenoson&#xD;
&#xD;
          3. Systolic blood pressure &lt; 90mm Hg&#xD;
&#xD;
          4. Active bronchospasm&#xD;
&#xD;
          5. Autonomic dysfunction as defined by prior diagnosis of:&#xD;
&#xD;
               -  Postural Orthostatic Tachycardia Syndrome (POTS)&#xD;
&#xD;
               -  Neurocardiogenic Syncope (NCS)&#xD;
&#xD;
               -  Neurally Mediated Hypotension (NMH)&#xD;
&#xD;
               -  Vasovagal Syncope&#xD;
&#xD;
          6. Hypovolemia&#xD;
&#xD;
          7. &gt; 40% Left main coronary stenosis&#xD;
&#xD;
          8. Moderate or &gt; valvular stenosis&#xD;
&#xD;
          9. Pericarditis/pericardial effusions&#xD;
&#xD;
         10. &gt; 70% carotid artery stenosis&#xD;
&#xD;
         11. Positive urine pregnancy test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brett E Fenster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 6, 2014</study_first_submitted>
  <study_first_submitted_qc>August 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2014</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Regadenoson</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

